Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

PURPOSE: To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response. PATIENTS AND METHODS: We conducted a multidisciplinary phase II study of sunitinib, an antivascular endothelial growth factor receptor tyros...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Zhu, Andrew X., Sahani, Dushyant V., Duda, Dan G., di Tomaso, Emmanuelle, Ancukiewicz, Marek, Catalano, Onofrio A., Sindhwani, Vivek, Blaszkowsky, Lawrence S., Yoon, Sam S., Lahdenranta, Johanna, Bhargava, Pankaj, Meyerhardt, Jeffrey, Clark, Jeffrey W., Kwak, Eunice L., Hezel, Aram F., Miksad, Rebecca, Abrams, Thomas A., Enzinger, Peter C., Fuchs, Charles S., Ryan, David P., Jain, Rakesh K.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2702235/
https://ncbi.nlm.nih.gov/pubmed/19470923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.9908
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items